Please login to the form below
Teva and Novartis settle patent lawsuit
Teva Pharmaceuticals will settle patent litigation with Novartis involving Teva's US generic version of antiviral medication Famvir
Teva Pharmaceuticals, US, has signed an agreement with Novartis to settle patent litigation involving Teva's US generic version of the Novartis-developed antiviral medication Famvir (famciclovir).
The settlement includes all claims for patent infringement and damages.
Under the terms of the agreement, Israel-based Teva will make an undisclosed one-time payment to Novartis plus ongoing royalties on US sales of its product, which is used to treat herpes and shingles.
Teva is among the top 15 global pharmaceutical companies and is a leading generic pharmaceutical company. Teva launched the generic version of Famvir in September 2007.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
-
Medical Editor
-
Competitive
-
Senior Leader
-
Exceptionally competitive salary
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
-
Healthcare Account Director
-
Competitive
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- Novartis and smartpatient launch app experience for wet AMD patients
- FDA delays BMS’ liso-cel decision, citing COVID-19 travel restrictions
- GSK, Medicago launch phase 2/3 clinical trials of plant-derived COVID-19 vaccine
- Finalists - PMEA
- CureVac says its COVID-19 vaccine can be stored at standard refrigerator temperature
- What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
- Environmental impact of in-person vs. virtual meetings
- Russia says its Sputnik V COVID-19 vaccine is 91.4% effective
- PMEA 2020: continuing to recognise excellence in improving patient outcomes
- The US celebrates five years of biosimilars on the market – a look to the past, present and future
- Live Webinar: Patient-Centered Digital Transformation
PMHub
OPEN Health
OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...
Latest intelligence
- What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
- ...
- Environmental impact of in-person vs. virtual meetings
- Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
- The US celebrates five years of biosimilars on the market – a look to the past, present and future
- Why the success of biosimilars in the US has been mixed...
Quick links
Infographics
